ER-100
Life Biosciences
ER-100 is an OSK partial-reprogramming gene therapy in an open-label Phase 1 eye study. Its developer reports 56-day safety observations in three glaucoma patients and exploratory visual-field changes in two.
Changing gene expression and cell state while preserving the function a tissue needs.
A molecular shift alone does not establish functional restoration.
Each dossier describes the mechanism, studies and development history of a research programme.
5 programmes and 2 articles in this edition.
Life Biosciences
ER-100 is an OSK partial-reprogramming gene therapy in an open-label Phase 1 eye study. Its developer reports 56-day safety observations in three glaucoma patients and exploratory visual-field changes in two.
NewLimit
NewLimit is screening reprogramming payloads for liver, vascular and immune cells. Its October 2026 update reports large-animal studies, additional screening and manufacturing scale-up; no human treatment results.
Retro Biosciences
Retro's reprogramming portfolio includes stem-cell and tissue approaches. Its collaboration with OpenAI has reported engineered transcription factors that improve pluripotency-marker expression in human cells. That laboratory result does not establish a clinical reprogramming therapy or additional years of human life.
Shift Bioscience
Shift searches for interventions that alter age-associated cell states. Its public portfolio separates the single-factor SB000 laboratory work from an SB101 antifibrotic siRNA programme with company-reported mouse evidence. Neither was verified as a human clinical rejuvenation study.
Altos Labs
Altos studies how cells regain health and resilience, combining experimental biology with computational modelling. This is an organisation-level research programme. Foundational cell and animal studies support its approach; no named clinical rejuvenation candidate or human outcome was verified in this dossier.

Reprogramming factors change how cells use their genes. Researchers are testing whether a controlled period of expression can restore selected functions while preserving cell identity.
Read article
Life Biosciences has reported day-56 ER-100 safety observations in three glaucoma patients. The open-label study is too small to establish a visual benefit.
Read article